<DOC>
	<DOCNO>NCT01435499</DOCNO>
	<brief_summary>The primary objective study evaluate safety feasibility administer allogeneic GM-CSF-secreting lethally irradiate whole melanoma cell vaccine ( `` melanoma GVAX '' ) , alone combination low dose cyclophosphamide ( CPM ) , adjuvant treatment patient surgically resect stage IIB-IV melanoma . Secondarily , investigator assess vitro correlate anti-melanoma immunization melanoma GVAX , include serological cellular immune response patient treat either vaccine alone vaccine give low dose CPM .</brief_summary>
	<brief_title>Safety Study Melanoma Vaccine ( GVAX ) With Without Cyclophosphamide Patients With Surgically Resected Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Any patient age â‰¥18 year melanoma cutaneous mucosal origin , clinicopathologic stage IIB , IIC , III IV completely resect Patients must able provide inform consent . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Life expectancy least 6 month . Adequate hematologic function . Adequate renal function Adequate hepatic function Patients gender must agree practice effective birth control study period least 4 week last treatment . Patients whose primary site melanoma ocular . Are undergo undergone past 4 week systemic treatment melanoma . Are undergo undergone past 2 week surgery focal radiation therapy . Have active systemic infection , coagulation disorder ( include therapeutic anticoagulation ) , major medical psychiatric illness . Are known positive hepatitis B surface antigen , antiHepatitis C Virus antiHuman Immunodeficiency Virus ( HIV ) antibody ( possible immune effect condition ) . Documented history autoimmune disease , example , systemic lupus erythematosus , sarcoidosis , rheumatoid arthritis , glomerulonephritis , vasculitis . Any form primary secondary immunodeficiency . This would include hereditary disorder ataxiatelangiectasia WiskottAldrich syndrome , acquire immune deficiency follow bone marrow transplantation . Requirement systemic steroid therapy immunosuppressive therapy . Have receive type cancer immunotherapy , include limited interleukin2 , interferon alfa melanoma vaccine . Have diagnose another invasive cancer within past 3 year . Radiographic evidence melanoma recurrence . Pregnant lactating woman . Known suspect hypersensitivity GMCSF , pentastarch , hetastarch , corn , Dimethyl sulfoxide , fetal bovine serum trypsin ( porcine origin ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>immunotherapy</keyword>
	<keyword>vaccine</keyword>
	<keyword>GVAX</keyword>
	<keyword>GM-CSF</keyword>
</DOC>